Table 3.
Study group | Adults, early onset | Adult onset | ||||
---|---|---|---|---|---|---|
na/nc | p value | OR (95% CI) | na/nc | p value | OR (95% CI) | |
Iceland | 617/30898 | 1.4×10-9 | 1.44 (1.28, 1.63) | 744/30898 | 0.064 | 1.11 (0.99, 1.23) |
Australia | 370/564 | 0.016 | 1.26 (1.04, 1.52) | 226/564 | 0.22 | 0.87 (0.70, 1.08) |
The Netherlands | 156/1564 | 0.0081 | 1.37 (1.09, 1.73) | 57/1564 | 0.55 | 1.12 (0.77, 1.63) |
Korea | 211/558 | 0.0049 | 1.49 (1.13, 1.96) | 1176/558 | 0.35 | 1.08 (0.92, 1.28) |
United Kingdom | 81/241 | 0.07 | 1.39 (0.97, 1.99) | 60/241 | 0.63 | 1.10 (0.74, 1.65) |
Combined non-icelandic | 818/2927 | 1.6×10-6 | 1.35 (1.19, 1.52) | 1519/2927 | 0.74 | 1.02 (0.91, 1.15) |
Combined all | 1435/33825 | 1.5×10-14 | 1.40 (1.28, 1.52) | 2263/33825 | 0.11 | 1.07 (0.99, 1.16) |
na/nc, number of asthmatics and controls; OR, odds ratio; CI, confidence intervals.
Adapted from Halapi, et al.22